Asian Stocks Rise as AI Chip Rally Lifts South Korea, Japan 
ANZ Home Loan Applications Drop 12% After Australia Property Tax Changes 
Alphabet Shifts AI Strategy Toward Commercial Growth, Goldman Sachs Says 
Trump Imposes New Tariffs on Drone Imports Over US Security Concerns 
Aviva First-Half Operating Profit Jumps 24% as Direct Line Deal Boosts Growth 
Pandora Shares Rise as Q2 Results Beat Forecasts, 2026 Outlook Raised 
Asian Stocks Rally as Cooling US Inflation Boosts Fed Rate Outlook 
Paramount Skydance Clears Regulatory Hurdles for Warner Bros. Discovery Deal 
US Dollar Slips as Softer PPI Data Eases Fed Rate Hike Expectations 
Bank of America to Buy Up to 49.9% Stake in Jio Credit for $1.92 Billion 
Nvidia Eyes $3 Billion Investment in SoftBank-Backed AI Data Center 
European Stocks Steady as U.S.-Iran War, Euro Zone Data Keep Investors Cautious 
Google Pushes Gemini AI Overhaul as Sergey Brin Targets Model Supremacy 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Canada-US Trade Talks Gain Momentum Ahead of Aug. 19 Tariff Deadline 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Add as a preferred source on Google
SK pharmteco, a global Contract Development and Manufacturing Organization (CDMO) and a subsidiary of SK Inc., just launched its second production plant in France. With this new facility, it has now increased its production of viral vectors to double.
The Korea Economic Daily, Yposkesi, an SK pharmteco's subsidiary and one of Europe's largest CDMOs for viral vector manufacturing in Cell and Gene Therapies, finished up the construction of the new 5,000 square meter facility for industrial bioproduction for cell and gene therapy.
It was added that Yposkesi is planning to launch the commercial operations of the vector factory in 2024. A total of $65.3 million was put in for the construction of this facility. The companies may now produce up to 75 batches of cell and gene therapy products per year.
These productions are said to be one of the most advanced personalized types of medicine for the treatment of rare disorders and serious illnesses. The demand for such treatments is growing as they were proven to be effective and with fewer side effects too. These give good results since they are made with patients' own genes and cells.
"It is with great pleasure and pride that today we open the new Yposkesi viral vector manufacturing facility. This twin site enables us to stay up to pace with demand by producing larger quantities of C> products approved for commercialization," Yposkesi's chief executive officer, Alain Lamproye, said in a press release. "The facility's state-of-the-art design will allow us, in collaboration with our clients, to manufacture advanced therapies more efficiently and cost-effectively in line with their C> pipelines and commitments, making these treatments more accessible to patients."
SK Inc. head of Bio Investment Center, Kim Yeon Tae Kim, also said they "anticipate Yposkesi to become a leading global Cell and Gene Therapy Contract Development and Manufacturing Organization through the synergy achieved with the Center for Breakthrough Medicines (CBM), a US-based cell and gene therapy CDMO and a subsidiary of SK pharmteco."
Photo by: SK Inc. Press Release
